Publication:
Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents

dc.contributor.authorTATAR, ESRA
dc.contributor.authorKABASAKAL, LEVENT
dc.contributor.authorsKucukguzel, S. Gueniz; Tatar, Esra; Rollas, Sevim; Sahin, Fikrettin; Gulluce, Medine; De Clercq, Erik; Kabasakal, Levent
dc.date.accessioned2022-03-12T16:00:05Z
dc.date.accessioned2026-01-10T18:55:37Z
dc.date.available2022-03-12T16:00:05Z
dc.date.issued2007
dc.description.abstractThree novel series of 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid derivatives namely 4-substituted-1,2,4-triazoline-3-thiones (4a-g); 2-substituted- 1.3.4-thiadiazoles (5a-g) and 2-substituted- 1,3,4-oxadiazoles (6a-g) have been synthesized. Twenty-one of the newly synthesized compounds were tested against various bacteria, fungi, yeast species and virus. In addition, we have replaced the carboxylic acid group of diflunisal with heterocycles and the anti-inflammatory activity of heterocycles reported here. Compound (5d) showed activity against Escherichia coli Al and Streptococcuspyogenes ATCC-176 at a concentration of 31.25 mu g/mL, whereas cefepime, the drug used as standard, has been found less active against the bacteria mentioned above. Compound (4b) has exhibited activity against Aspergillus variecolor and Trichophyton rubrum at a concentration of 31.25 and 15.25 mu g/mL, whereas Amphotericin B, the drug used as standard, has been found less active against the yeast and fungi. The highest antiviral activity was found in the 1,3,4-thiadiazole derivative (5a) having a methyl group at 2nd position against Sindbis virus at 9.6 mu g/mL. Compound (4c) exhibited the highest anti-inflammatory activity (73.03%) whereas diflunisal, the drug used as standard, has been found less active (24.16%). Compound (5f) presented similar antinociceptive activity with the standard drug (paw withdrawal latency was 19.21 s compared to that of diflunisal which was 19.14 s, in hot plate test). (c) 2007 Elsevier Masson SAS. All fights reserved.
dc.identifier.doi10.1016/j.ejmech.2006.12.038
dc.identifier.issn0223-5234
dc.identifier.pubmed17418454
dc.identifier.urihttps://hdl.handle.net/11424/224587
dc.identifier.wosWOS:000247992100001
dc.language.isoeng
dc.publisherELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
dc.relation.ispartofEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subject1,2.4-Triazoline-3-thione
dc.subject1,3,4-Thiadiazole
dc.subject1,3,4-Oxadiazole
dc.subjectdiflunisal
dc.subjectanti-inflammatory agents
dc.subject1,3,4-THIADIAZOLE DERIVATIVES
dc.subjectBIOLOGICAL-ACTIVITIES
dc.subjectANTIBACTERIAL
dc.subjectINHIBITORS
dc.subjectEXTRACT
dc.subjectDESIGN
dc.subjectDRUG
dc.subjectAIDS
dc.titleSynthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage901
oaire.citation.issue7
oaire.citation.startPage893
oaire.citation.titleEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
oaire.citation.volume42

Files